Guillain-Barre syndrome
ICD-10 G61.0 is a billable code used to indicate a diagnosis of guillain-barre syndrome.
Guillain-Barre syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy characterized by rapid onset of muscle weakness and areflexia, often following a respiratory or gastrointestinal infection. The condition is believed to be an autoimmune response where the body's immune system mistakenly attacks the peripheral nerves, leading to demyelination and subsequent nerve conduction block. Patients typically present with symmetrical weakness that can progress to paralysis, often starting in the legs and ascending to the upper body. Diagnosis is supported by clinical findings, cerebrospinal fluid analysis showing albuminocytologic dissociation, and electrodiagnostic studies demonstrating demyelination. GBS can lead to significant morbidity, requiring close monitoring and supportive care, including respiratory support in severe cases. Recovery can take weeks to months, but some patients may experience residual weakness or other long-term effects.
Detailed neurological examination findings, results of electrodiagnostic studies, and clinical history.
Patients presenting with acute onset of weakness, history of recent infections, and abnormal nerve conduction studies.
Ensure documentation reflects the acute nature and progression of symptoms, as well as any complications.
Assessment of functional status, rehabilitation goals, and progress notes.
Patients undergoing rehabilitation post-GBS for strength and mobility improvement.
Documenting the impact of GBS on daily activities and the need for assistive devices.
Used to confirm diagnosis of GBS through electrodiagnostic testing.
Document the specific nerves tested and results.
Neurologists should ensure comprehensive documentation of findings.
Common symptoms include rapid onset of muscle weakness, areflexia, tingling sensations, and in severe cases, paralysis. Symptoms often start in the legs and can ascend to the upper body.
